Evaluation of plasma osteopontin level as a biomarker for hepatocellular carcinoma in Egyptian patients

Keddeas, Marcel William; Abo-Shady, Rania A.

doi:10.1097/01.elx.0000397024.87552.42

Cited by 5 publications

(5 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…17 Investigation of usefulness of serum GPC3 level showed that GPC3 protein is an early sensitive and specific serum marker for initial diagnosis of HCC 7,18 and for HCC recurrence after liver transplantation. 19 In the present study, In group  (HCC), the age of the patients ranged between 46 and 53.3 years with mean age (48.80±1.36) years., This is consistent with another results 20 , that found that the age of the patients with HCC ranged from 40 to 72 years. In addition, our finding is consistent with 13 findings, where patients of the age group 40-59 years were 3.7 times and of age group > 60 years were 11 times more at risk to develop HCC.…”

Section: Discussionsupporting

confidence: 93%

Value of Serum Glypican 3 as a Predictive Tool for Early Diagnosis of Hepatocellular Carcinoma (Hcc)

Mohamed

2020

Al-Azhar International Medical Journal

View full text Add to dashboard Cite

Background: Hepatocellular carcinoma (HCC) is one of the most aggressive malignancies worldwide and one of the main causes of cancerrelated mortality globally. Serum alpha-fetoprotein (AFP) has insufficient sensitivity and specificity for detection of hepatocellular carcinoma (HCC). Estimation of serum level of certain up regulated proteins as glypican-3 (GPC-3) in HCC could be a promising biomarker for screening and early HCC detection. Recently glypican-3 (GPC-3) was suggested as novel biomarkers for the detection HCC. Objective: To determine the role of serum GPC-3 in the early diagnosis of HCC Methods: The study included eighty subjects: 30 patients with HCC and elevated AFP. ; 30 with liver cirrhosis in addition, 20 healthy subjects were included as a control group. Clinical and radiological features (abdominal ultrasonography and/or abdominal triphasic computed tomography) were recorded. Liver function tests, complete blood cell count, and serum AFP were measured. Serum GPC-3 values were determined by ELISA technique. Results: This study revealed that: Serum levels of GPC-3 were significantly elevated in patients with HCC compared with liver cirrhosis and control groups (p < 0.001). Also, serum GPC-3 levels with cutoff value of 2.72 ug/L, had a sensitivity (93.0%) and specificity (49 % .) Conclusion: Glypican-3 should be included in the screening programs for early HCC detection among cirrhotic patients as a rapid, sensitive, noninvasive and cost-effective diagnostic biomarker.

show abstract

Section: Discussionsupporting

confidence: 93%

Value of Serum Glypican 3 as a Predictive Tool for Early Diagnosis of Hepatocellular Carcinoma (Hcc)

Mohamed

2020

Al-Azhar International Medical Journal

View full text Add to dashboard Cite

show abstract

“…In the current study the mean age in cirrhotic group was (58.20 ± 9.05) and the mean age in HCC group was (58.63 ± 9.40), with male predominance in both groups with percentage of 70% in cirrhosis group and 83.3% in HCC group. These results agree with the study conducted by Keddeas and Abo-shady (13) who found that the mean age of HCC patients ranged from 40 to 72 years and, in accordance with El-Zayadi et al (14) who found that HCC was much prevalent in males (85.8%) than females (14.2%). This could be explained by what Salama and Chen (15) stated that these results are due to more exposure of males to risk factors.…”

Section: Discussionsupporting

confidence: 92%

Value of Glypican-3 as a Diagnostic and Prognostic Biomarker for Hepatocellular Carcinoma before and after Treatment. A Prospective Study

Isaac¹,

Badawy²,

Mohamed³

et al. 2021

The Egyptian Journal of Hospital Medicine

View full text Add to dashboard Cite

Background: Hepatocellular carcinoma is a highly prevalent tumor globally and the world's second leading cause of cancer-related deaths. Glypican-3, a heparan sulfate proteoglycan expressed on the surface of HCC cells, has emerged as a new molecule with a strong link to occurrence and progression of HCC. Objective: This study was done to determine the role of Glypican-3 in diagnosis of HCC and its prognostic value following different treatment modalities. Patients and methods: The study included thirty patients with liver cirrhosis and HCC on top, and thirty patients with liver cirrhosis without HCC. Standard laboratory investigations, abdominal ultrasound and triphasic computed tomography were done for all patients. Serum alpha fetoprotein and Glypican-3 were measured in all patients before and one month after different treatment modalities. Results: Glypican-3 was significantly higher in HCC group (2.28 ± 0.97) in comparison to cirrhosis group (0.56 ± 0.31) with P-value <0.001. Glypican-3 level was higher in larger sized lesions with p value 0.023, one month after treatment with different modalities, Glypican-3 declined significantly (from 2.28 ± 0.97 to 1.44 ± 0.93) with p value <0.001. At a cutoff point of > 1.1 ng/ml Glypican-3 has 93.3% sensitivity, 96.67% specificity, 96.6% PPV and 93.5% NPV for detection of HCC. Conclusion: Glypican-3 can be a valuable diagnostic marker for HCC diagnosis and prognosis after various treatment modalities and may be complementary to alpha fetoprotein increasing overall sensitivity of HCC detection.

show abstract

“…. 15 On the other hand the current study results are somewhat higher than an Egyptian study done by Azab et al, (2011) 34 where blood RASSF1A promoter hypermethylation was detected in 70% of HCC group, 28.5% of HCV-associated liver patients and was not detected in any of the healthy control subjects.…”

Section: Discussioncontrasting

confidence: 78%

Role of Hypermethylation (Rassf1a) Promoter Gene Among Patients With Hepatocellular Carcinoma

Mohamed

2020

Al-Azhar International Medical Journal

View full text Add to dashboard Cite

Background: Hepatocellular carcinoma (HCC) is one of the most aggressive malignancies worldwide and one of the main causes of cancer-related mortality globally. Its incidence is increasing at alarming rates. The presence of cirrhosis is the major risk factor and this is largely due to chronic HCV and HBV infection. Serum alpha-fetoprotein (AFP) has insufficient sensitivity and specificity for detection of hepatocellular carcinoma (HCC). Aberrant hypermethylation of tumor suppressor genes e.g( RASSF1A) is one of the most frequent and early mechanisms involved in HCC development, so that it could help to select high-risk populations and thus to modulate the indications of screening procedures. Objectives: To evaluate the frequency of tumor suppressor gene RASSF1A hypermethylation in whole blood from HCC patients. Methods: The study included eighty subjects : 30 patients with HCC and elevated AFP. ; 30 with liver cirrhosis In addition, 20 healthy subjects were included as a control group. Clinical and radiological features (abdominal ultrasonography and/or abdominal triphasic computed tomography) were recorded. Liver function tests, complete blood cell count, and serum AFP were measured.. Detection of promotor methylation status of RASSF1A using methylation specific PCR. Results: The obtained results showed a significant RASSF1A promoter hypermethylation in HCC subjects that was 83.3% in comparison to healthy control subjects as well as in comparison to subjects with non HCC chronic liver disease. Conclusion: Detection of methylated RASSF1A promoter is useful marker for HCC screening in high risk vulnerable patients and early HCC diagnosis.

show abstract

Evaluation of plasma osteopontin level as a biomarker for hepatocellular carcinoma in Egyptian patients

Cited by 5 publications

References 17 publications

Value of Serum Glypican 3 as a Predictive Tool for Early Diagnosis of Hepatocellular Carcinoma (Hcc)

Value of Serum Glypican 3 as a Predictive Tool for Early Diagnosis of Hepatocellular Carcinoma (Hcc)

Value of Glypican-3 as a Diagnostic and Prognostic Biomarker for Hepatocellular Carcinoma before and after Treatment. A Prospective Study

Role of Hypermethylation (Rassf1a) Promoter Gene Among Patients With Hepatocellular Carcinoma

Contact Info

Product

Resources

About